Salazosulfadimidine

Salazosulfadimidine

SCHEMBL150333

Cc1cc(C)nc(NS(=O)(=O)c2ccc(N=Nc3ccc(O)c(C(=O)O)c3)cc2)n1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 1/20 0.63
ALDH1A1 P00352 3/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
CYP2C9 P11712 2/20 0.62
TSHR P16473 2/20 0.62
LMNA P02545 2/20 0.62
BLVRB P30043 2/20 0.62
ABCC3 O15438 1/20 0.62
ABCC4 O15439 1/20 0.62
USP2 O75604 1/20 0.62
SLCO2B1 O94956 1/20 0.62
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
MMP1 P03956 1/20 0.62
ABCB1 P08183 1/20 0.62
MAPT P10636 1/20 0.62
HPGD P15428 1/20 0.62
NFKB1 P19838 1/20 0.62
TBXAS1 P24557 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salazosulfadimidine SCHEMBL31424085 1.00 AMY1A (0.63) AMY1AALDH1A1MEN1KMT2ACYP2C9
SCHEMBL9652544 0.86 AMY1A (0.53) AMY1AALDH1A1MEN1KMT2ACYP2C9
SCHEMBL9652528 0.86 AMY1A (0.53) AMY1AALDH1A1MEN1KMT2ACYP2C9
SCHEMBL10834896 0.84 AMY1A (0.61) AMY1AALDH1A1MEN1KMT2ATSHR
SCHEMBL10834904 0.84 AMY1A (0.61) AMY1AALDH1A1MEN1KMT2ATSHR
SCHEMBL29371752 0.84 AMY1A (0.53) AMY1AALDH1A1MEN1KMT2ACYP2C9
SCHEMBL10834640 0.84 AMY1A (0.60) AMY1AALDH1A1MEN1KMT2ATSHR
SCHEMBL10834633 0.84 AMY1A (0.60) AMY1AALDH1A1MEN1KMT2ATSHR
SCHEMBL4908605 0.80 PHLPP2 (0.70) ALDH1A1MEN1KMT2ACYP2C9TSHR
SCHEMBL4908604 0.80 PHLPP2 (0.70) ALDH1A1MEN1KMT2ACYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022040799-A1 ANTIMICROBIAL COMPOSITION GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) 2022-03-03 WO claimed
US-10449247-B2 Compositions and methods for enhancing immune response AVIVAGEN INC. (CA) 2019-10-22 US claimed
EP-2953624-B1 METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS LUODA PHARMA LTD (IE) 2019-08-21 EP claimed
US-10092578-B2 Active agents and their oligomers and polymers POLYMERIX CORPORATION (US) 2018-10-09 US claimed
US-20170368185-A9 METHOD OF PREPARING DENDRITIC DRUGS CHAI MINGHUI (CN) 2017-12-28 US claimed
US-20160206746-A1 METHOD OF PREPARING DENDRITIC DRUGS CHAI MINGHUI (CN) 2016-07-21 US claimed
CN-105492004-A Method of treating topical microbial infections LUODA PHARMA PTY LTD 2016-04-13 CN claimed
CN-105492005-A Methods of treating microbial infections including mastitis LUODA PHARMA PTY LTD 2016-04-13 CN claimed
US-20160000748-A1 METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS Luoda Pharma Limited (IE) 2016-01-07 US claimed
US-20150366797-A1 METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS Luoda Pharma Limited (IE) 2015-12-24 US claimed
EP-0792371-A4 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO INC (US) 1998-12-30 EP claimed
WO-1998041688-A1 SECURITY PAPER GEORGIA-PACIFIC CORPORATION, INC. (US) 1998-09-24 WO claimed
WO-1998022114-A1 A METHOD FOR PROMOTING TISSUE REPAIR DUMEX-ALPHARMA A/S (DK) 1998-05-28 WO claimed
EP-0792371-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-09-03 EP claimed
EP-0786999-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-08-06 EP claimed
US-5543417-A 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent MERCK & CO., INC. (US) 1996-08-06 US claimed
WO-1996012817-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1996012487-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000748-A1 METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS TSLP, CCL11, IL17A AMY1A 3328/4885ALDH1A1 2871/4885MEN1 3888/4885
US-20150366797-A1 METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS LCT, TSLP, MLEC AMY1A 2557/4885ALDH1A1 4040/4885MEN1 3344/4885
US-20160206746-A1 METHOD OF PREPARING DENDRITIC DRUGS MYD88, TLR3, TLR6 AMY1A 4842/4885ALDH1A1 3848/4885MEN1 3220/4885
US-20170368185-A9 METHOD OF PREPARING DENDRITIC DRUGS MYD88, TLR3, TLR6 AMY1A 4842/4885ALDH1A1 3848/4885MEN1 3220/4885
US-10092578-B2 Active agents and their oligomers and polymers ALG1, DDOST, IDUA AMY1A 1159/4885ALDH1A1 2906/4885MEN1 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.